Vaccination Efficacy of Mitoxantrone-Treated CT-26 Cells Under Different Drug Concentrations and Vaccination Intervals
Molecules · 23.10.2026 · 31 (21) · 3827
DOI: 10.3390/molecules31213827 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 23.10.2026. Verfasst von Se Won Na und 3 weiteren Autor:innen. Beteiligte Einrichtung: KM Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea. Hauptthemen laut MEDLINE: Mitoxantrone, Cancer Vaccines, Colonic Neoplasms, Antineoplastic Agents. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Institute of Oriental Medicine.
Abstract (Originalsprache)
Immunogenic cell death (ICD) converts dying tumor cells into an anticancer vaccine, yet whether protection depends on how those cells are prepared and when they are given has rarely been examined. Using mitoxantrone (MTX), a clinically approved small molecule classified as an ICD inducer, we examined both variables in the murine CT-26 colon carcinoma model. MTX reduced viability in a concentration-dependent manner and induced extracellular ATP release. The total extent of cell death, however, was similar across concentrations, indicating that the concentration-dependent loss of viability was not accompanied by a proportional increase in cell death. What differed was the composition of the dying population, which shifted from early to late apoptotic cells as the concentration increased. Prophylactic vaccination with MTX-treated cells protected BALB/c mice, leaving 75.0–87.5% of animals tumor-free after vaccination at 1 μM and 37.5–62.5% at 3 μM across independent experiments. Protection increased with the interval between vaccination and challenge, with 0%, 50.0%, and 87.5% of animals tumor-free after simultaneous injection, a 3-day interval, and a 7-day interval, respectively. Cells killed completely by freeze–thaw were inactive as a vaccine, and cisplatin-treated cells conferred only a marginal delay, whereas responders to MTX-treated cells resisted rechallenge for the remainder of the observation period. Taken together, these results show that use of an ICD-inducing drug alone is not sufficient for effective dying-cell vaccination and that protective efficacy is influenced by vaccine preparation and by the interval between vaccination and tumor challenge, rather than by the extent of cell death alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- KM Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
- Department of Pharmaceutical Engineering, Gyeongsang National University, Jinju 52828, Republic of Korea.
- Department of Science in Korean Medicine, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
- KIOM School, University of Science & Technology (UST), Daejeon 34054, Republic of Korea.
ORCID-Profile: Se Won Na, Mibae Jeong, Mi-Kyung Jeong, Jaemoo Chun
Förderung
- Korea Institute of Oriental Medicine
Zitieren
APA
Na, S. W., Jeong, M., Jeong, M. K., & Chun, J. (2026). Vaccination Efficacy of Mitoxantrone-Treated CT-26 Cells Under Different Drug Concentrations and Vaccination Intervals. Molecules, 31(21), 3827. https://doi.org/10.3390/molecules31213827
Vancouver
Na SW, Jeong M, Jeong MK, Chun J. Vaccination Efficacy of Mitoxantrone-Treated CT-26 Cells Under Different Drug Concentrations and Vaccination Intervals. Molecules. 2026;31(21):3827. doi:10.3390/molecules31213827
BibTeX
@article{Na2026,
author = {Na, Se Won and Jeong, Mibae and Jeong, Mi-Kyung and Chun, Jaemoo},
title = {Vaccination Efficacy of Mitoxantrone-Treated CT-26 Cells Under Different Drug Concentrations and Vaccination Intervals},
journal = {Molecules},
year = {2026},
volume = {31},
number = {21},
pages = {3827},
doi = {10.3390/molecules31213827}
}
EUVIMED